Risedronate Sodium Tablet, Film Coated
Product Images NDC 60505-3165

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 60505-3165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Risedronatefig3 (Figure3)

A bar chart comparing mean percentage change in bone mineral density (BMD) with standard error bars at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart contrasts results for placebo and Risedronate Sodium Tablets 5 mg groups, showing BMD changes for each group with sample sizes indicated (n=52 to n=80).*

FDA Label Image

Risedronatefig4 (Figure4)

A bar graph comparing the mean percentage change in Bone Mineral Density (BMD) at the Lumbar Spine, Femoral Neck, and Femoral Trochanter between a placebo group and a group treated with Risedronate Sodium Tablets 5 mg. The graph includes sample sizes (n) for each group and shows higher BMD changes with Risedronate Sodium across all three sites.*

FDA Label Image

Risedronatefig5 (Figure5)

A bar chart comparing incidence percentages between placebo and Risedronate Sodium 5 mg tablets among patients continuing glucocorticoid treatment, patients initiating glucocorticoid treatment, and combined groups. The chart shows incidence values on the vertical axis and group categories on the horizontal axis.*

FDA Label Image

Risedronatefig6 (Figure6)

A line graph comparing the percentage change over visit days between two treatments: Didronel 400 mg and Risedronate Sodium 30 mg tablets. The x-axis represents visit days up to 600, while the y-axis shows percentage change. Data points include sample sizes for treatment, follow-up, and extended follow-up periods.*

FDA Label Image

Rise150mgblscarton1tab (Rise150mgblscarton1tab)

Packaging label for Risedronate Sodium Tablet, USP 150 mg film-coated tablet by Apotex Corp. The label indicates the product is a once-a-month oral tablet. It includes instructions for use, storage conditions, dispensing instructions for pharmacists, and manufacturer details. The carton also features barcode and child-resistant packaging warnings.*

FDA Label Image

Rise35mgblscarton4tabs (Rise35mgblscarton4tabs)

Packaging label for Risedronate Sodium Tablets, USP 35 mg, film-coated, once-a-week oral tablets by Apotex Corp. The carton contains 4 tablets (1 x 4 unit of use). The label includes instructions for use with images, storage conditions, and barcode. The product is for prescription use only.*

FDA Label Image

Rise75mg2s (Rise75mgblscarton2tabs)

Packaging label for Risedronate Sodium Tablets, USP 75 mg film-coated tablets by Apotex Corp. The label indicates a package of 2 tablets (1 x 2 unit-dose) designed for two consecutive days-a-month dosing. It includes instructions for use, storage information, manufacturer details, and a barcode for pharmacy label use.*

FDA Label Image

Risedronatestructure (Risedronatechemstructure)

Chemical structure of Risedronate Sodium, depicting its molecular components including phosphate groups, hydroxyls, a pyridinyl ring, sodium ion, and hydration with 2.5 water molecules.*

FDA Label Image

Risedronatefig1 (Risedronatefig1)

A bar chart titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA' comparing the percentage of patients with fractures at various body sites for placebo versus risedronate sodium tablets 5 mg groups. Body sites include All, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle, with placebo generally showing higher fracture percentages than risedronate sodium tablets.*

FDA Label Image

Risedronatefig2 (Risedronatefig2)

A bar chart titled 'Figure 2 Change in BMD from Baseline 2-Year Prevention Study' comparing mean percentage change in bone mineral density (BMD) with standard error at the lumbar spine, femoral neck, and femoral trochanter. The chart contrasts placebo with Risedronate sodium 5 mg tablets in groups of approximately 90 to 103 subjects.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.